AstraZeneca

Cancer metastasis
#AstraZeneca #Cancer research #Immuno-oncology #Interview #Oncology

Global breakthroughs in cancer drug discovery

Listen to this article on the DDW Podcast: AstraZeneca UK has appointed David Brocklehurst as Head of Oncology in the UK. He spoke with DDW’s Megan Thomas about how AstraZeneca is innovating to displace chemotherapy and research areas of significance. MT: What will you be focusing on in your new role?… Read More

#Cancer Research #Exclusive Content #Opinion

Qureight platform image
#AI / data analytics / healthtech / informatics #AstraZeneca #Lung disease #Qureight

Qureight and AZ collaborate on lung disease research

Cambridge data analytics company Qureight has announced a multi-year strategic research collaboration with AstraZeneca. The agreement will allow AstraZeneca to use Qureight’s proprietary platform and artificial intelligence (AI) technology to conduct research across a range of complex lung diseases. It is hoped that this will help… Read More

#News

Baby on a respirator - RSV
#AstraZeneca #FDA #Monoclonal antibodies #Paediatrics #Respiratory syncytial virus

Monoclonal antibody to prevent RSV in babies approved in US

The US Food and Drug Administration (FDA) has approved AstraZeneca’s Beyfortus (nirsevimab-alip) for the prevention of Respiratory Syncytial Virus (RSV) lower respiratory tract disease in neonates and infants born during or entering their first RSV season. The drug is also approved in children up to 24 months of age who… Read More

#News #Regulatory

Stock market
#AstraZeneca #Business #Cancer research #Lung cancer #Oncology #Trial data

AstraZeneca stock value falls by 8%

Shares in AstraZeneca fell by 6% on July 3 when the company published the first results from its Phase III trial for datopotamab deruxtecan (Dato-DXd) and continued to fall throughout the day, though there was some recovery on July 4. It was reported that the therapy demonstrated statistically significant improvement… Read More

#Business & Investment #News #Trending News

Amazon Rainforest
#AstraZeneca #Carbon emissions #Environmental #Environmental impact #Sustainability

AZ to invest $400 million in reforestation and biodiversity

AstraZeneca has announced a $400 million investment in its global AZ Forest programme, raising its commitment to plant 200 million trees by 2030. This includes new or expanded projects in Brazil, India, Vietnam, Ghana and Rwanda that will contribute to the company’s climate action, restore nature,… Read More

#News

#ABPI #AstraZeneca #Daiichi Sankyo #LEO Pharma #Prescription Medicines Code of Practice Authority (PMCPA) #Regulatory

Pharma watchdog calls out Leo, AZ and Daiichi Sankyo for misleading ads 

The Prescription Medicines Code of Practice Authority (PMCPA), a self-regulatory body which administers the Association of the British Pharmaceutical Industry (ABPI) Code of Practice for the Pharmaceutical Industry, have opened cases against Leo Pharma, AstraZeneca and Daiichi Sankyo for bringing discredit upon, and reducing confidence in, the pharmaceutical industry. AstraZeneca  … Read More

#News #Regulatory

Kidneys
#AstraZeneca #Cardiovascular disease #Chronic kidney disease (CKD) #Heart failure #Real world data

RWE shows risk of cutting RAASi medication in cardiorenal patients

A real-world evidence (RWE) study has shown the negative consequences of reducing or discontinuing renin-angiotensin-aldosterone system inhibitor (RAASi) medication in patients experiencing hyperkalaemia (HK). One analysis from AstraZeneca’s ZORA study showed that discontinuation of RAASi treatment following a HK episode in cardiorenal patients with chronic kidney… Read More

#News

#AstraZeneca #Drug development #FDA #GSK #HER2 #National Institute for Health and Care Excellence (NICE) #Pfizer #Regulatory

New episode: DDW Highlights 19 June

The latest episode of the DDW Highlights podcast is now available to listen to below. DDW’s Megan Thomas narrates five key stories of the week to keep DDW subscribers up-to-date on the latest industry updates.  Regulatory approvals and industry guidelines are key to the continued development and discovery of drugs,… Read More

#News

#AstraZeneca #Drug development #FDA #GSK #HER2 #National Institute for Health and Care Excellence (NICE) #Pfizer #Regulatory

This week in drug discovery (12-16 June)  

News round-up for 5-9 June by DDW Multimedia Editor Megan Thomas.  Regulatory approvals and industry guidelines are key to the continued development and discovery of drugs, which is a common theme throughout this week’s news highlights, including an FDA approval for Pfizer, a NICE recommendation… Read More

#News

Non-small cell lung cancer
#American Society of Clinical Oncology #ASCO #AstraZeneca #Cancer research #Lung cancer #Oncology #Phase III trial

Lung cancer pill reduced risk of death by more than half

Positive results from the ADAURA Phase III trial showed AstraZeneca’s Tagrisso (osimertinib) demonstrated a statistically significant and clinically meaningful improvement in overall survival (OS) compared to placebo. The trial assessed osimertinib as an adjuvant treatment of patients with early-stage (IB, II and IIIA) epidermal growth factor… Read More

#Cancer Research #News #Trending News

Male patient with doctor
#AstraZeneca #FDA #Merck #Oncology #Phase III trial #Prostate cancer

FDA extends US approval for olaparib in prostate cancer

Lynparza (olaparib) has been approved in the US for the treatment of adult patients with deleterious or suspected deleterious BRCA-mutated (BRCAm) metastatic castration-resistant prostate cancer (mCRPC). The PARP inhibitor, developed by AstraZeneca and Merck (MSD), is approved in combination with abiraterone and prednisone or prednisolone. This approval was based on… Read More

#News #Regulatory

Molecular glues
#AstraZeneca #Francis Crick Institute #Molecular research #Oncology #University College London

Molecular glues could tackle ‘undruggable’ disease targets

UK researchers at the Francis Crick Institute, Imperial College London and AstraZeneca will advance the discovery of new ‘molecular glues’ to treat a range of different diseases, thanks to a £11.2 million combined investment. The investment includes a Prosperity Partnership grant from the Engineering and Physical… Read More

#Editor's Choice #News

Asthma inhaler
#Asthma #AstraZeneca #Clinical trial #National Institute for Health and Care Excellence (NICE) #NHS England

Add-on treatment for severe uncontrolled asthma approved 

The National Institute for Health and Care Excellence (NICE) has issued final draft guidance recommending AstraZeneca’s Tezspire (tezepelumab).  The drug is approved for use within NHS England and NHS Wales and as add-on maintenance therapy in adult and adolescent patients, 12 years and older, with severe asthma… Read More

#News

Cancer research in laboratory
#AstraZeneca #Breast cancer #Cancer research #National Institute for Health and Care Excellence (NICE) #Oncology #Prostate cancer #The Institute of Cancer Research #UK

NICE approves olaparib for early-stage breast cancer and prostate cancer

The UK’s National Institute for Health and Clinical Excellence (NICE) has recommended that Lynparza (olaparib) can be used for NHS patients with both early-stage breast cancer and prostate cancer. Olaparib is PARP inhibitor that targets cancers linked to faulty BRCA1 or BRCA2 genes and works across many different cancer types. The… Read More

#News #Regulatory #Trending News

Nanoscale virus
#AstraZeneca #CAMECA #Drug discovery #Molecular medicine #Nanomedicine / nanotechnology

Nano technique reveals how drug molecules behave in cells

Researchers have made it possible to see at the nano level where a medicinal drug ends up in the cells and how much of it is needed for optimum treatment.  The technique enables the development of new pharmaceuticals and tailored treatments for diseases that have not previously… Read More

#Editor's Choice #News